N-Acetylcysteine to Combat COVID-19: An Evidence Review
N-acetylcysteine (NAC) has been used in clinical practice to treat critically ill septic patients, and more recently for COVID-19 patients. NAC has antioxidant, anti-inflammatory and immune-modulating characteristics that may prove beneficial in the treatment and prevention of SARS-Cov-2.
N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2
We hypothesize that NAC could act as a potential therapeutic agent in the treatment of COVID-19 through a variety of potential mechanisms, including increasing glutathione, improving T cell response, and modulating inflammation. In this article, we present evidence to support the use of NAC as a potential therapeutic agent in the treatment of COVID-19.
Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19
Thiols block the angiotensin-converting enzyme 2 thereby hampering penetration of SARS-CoV-2 into cells. Based on a broad range of antioxidant and anti-inflammatory mechanisms, which are herein reviewed, the oral administration of NAC is likely to attenuate the risk of developing COVID-19, as it was previously demonstrated for influenza and influenza-like illnesses.
N-acetylcysteine as a potential treatment for novel coronavirus disease 2019
Given this pandemic’s immense health risk, several drugs have been employed with and without clinical evidence for the treatment of COVID-19, NAC among them. Administration of NAC (oral, iv. or inhaled) as an adjuvant treatment in patients with mild–severe COVID-19 symptoms is worth considering as a cost–effective clinical strategy.
Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence
Considering the antioxidant and free radical scavenging action of N acetyl cysteine (NAC), its use might be useful in COVID-19 patients by decreasing the cytokine storm consequently decreasing the disease severity.